SCR-LIP-000671 · Claim · machine-readable JSON →
The proposed rationale for gestrinone in lipedema rests on hypothesised aromatase inhibition and estrogen-receptor blockade, supported only by theoretical and in vitro data.
General proposition consolidated from 1 earlier single-paper claims; each study's own result is shown as its finding.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- very low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 1 question(s)
- Dates
- 2026-11-20 → 2026-11-20
Structured evidence, machine-compiled — not a verdict.
Evidence over time
Evidence (1)
- Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women — Renke et al. (2024) ✓ verified — consistent · review · 2024 · reading confidence: high
“Mecanismo proposto para o lipedema: na doença há superexpressão de aromatase no tecido adiposo, aumentando a conversão de androgênios em estrogênios e alimentando a fisiopatologia; a gestrinona inibiria a aromatase e bloquearia receptores estrogênicos.”
Review proposes gestrinone for lipedema based on aromatase overexpression in lipedema adipose tissue, hypothesising aromatase inhibition and estrogen-receptor blockade; presents only in vitro cell-viability data (MTT, MDA-MB-231 and Huh7), no clinical trial.
The article is a narrative/mechanistic review that proposes gestrinone use in lipedema as a new application, offering a speculative aromatase-inhibition rationale and only in vitro cell data; it provides no clinical efficacy evidence in lip
Context (PECO)
Answers these questions
Gaps & caveats
Change log
- 2026-11-20 — created_by_consolidation · general proposition consolidated from SQ-LIP-000016